

FOR IMMEDIATE RELEASE
10 August 2007



London Genetics enhances its partnering capabilities by establishing a Scientific Advisory Board

- Leading experts in genetics and genomics will provide insight into available expertise and resources in London and advise on project design -

London, 10 August 2007... London Genetics Limited, a commercial company that facilitates and manages partnerships between the healthcare industry and London centres of excellence in genetics and genomics-based medical research, has today announced the formation of a Scientific Advisory Board. Consisting of leading authorities at the forefront of genetics and genomics research from seven of London's top academic institutions, the Scientific Advisory Board will provide expert advice on industrial partnerships that make use of their institutions' unique resources.

With their combined experience in basic, clinical and translational research and their insight into the facilities and expertise available within their institutions, the members of the Scientific Advisory Board are ideally placed to advise London Genetics on available partnership opportunities and optimum study design.

Mark Caulfield, Professor of Clinical Pharmacology at Queen Mary, University of London will Chair the Scientific Advisory Board, which will include the following leaders from London Genetics' other partner institutions:

- Tim Aitman, Professor of Clinical and Molecular Genetics, Imperial College London
- Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research
- Dr Aroon Hingorani, British Heart Foundation Senior Research Fellow, Division of Medicine, University College, London
- Professor Ellen Solomon, Head, Medical and Molecular Genetics, King's College London
- Professor Brendan Wren, Head of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine
- Professor Nick Carter, Head, Clinical Developmental Sciences, St George's, University of London
- Shirley Hodgson, Professor of Cancer Genetics, St George's, University of London

Mark is a renowned expert in the genetics of hypertension, and since 1996 he has been the National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study. He will bring his experience of successfully managing large scale genetics studies to London Genetics.

Commenting on today's appointments, Professor Stephen Smith, Chairman of the Board of Directors of London Genetics and Principal of the Faculty of Medicine, Imperial College London said: "*We are delighted to be working with such a distinguished and talented panel of individuals. Their contribution and advice will be crucial for London Genetics' success and will help the company attain its ambition to establish London as the leading centre for genetics medicine.*"

- ENDS-

Notes for editors

About London Genetics

London Genetics is a commercial company, funded by the London Development Agency that facilitates and manages partnerships between the healthcare industry and London centres of excellence in genetics and genomics-based medical research. London Genetics provides access to an extensive range of facilities and resources through a consortium of seven of London's top science and medical Institutions: Imperial College London; The Institute of Cancer Research; King's College London; The London School of Hygiene and Tropical Medicine; Queen Mary University of London; St George's University of London; and University College London. More information on London Genetics is available at: www.londongenetics.co.uk

For more information contact:

London Genetics
Nick Lench, Chief Executive Officer
Tel: +44 (0)20-7594-3746
Email: n.lench@imperial.ac.uk

Harry Singh
Director of Operations
Tel: +44 (0)20-7594-1468
Email: h.singh@imperial.ac.uk

Northbank Communications
Gemma Price, Holly Griffiths, Katja Stout
Tel: 020 7268 3002
Email: g.price@northbankcommunications.com